Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan
· Delayed Price · Currency is TWD 48.60
-3.20 (-6.18%)
Mar 9, 2026, 1:30 PM CST
Senhwa Biosciences Revenue
Senhwa Biosciences had revenue of 330.00K TWD in the quarter ending September 30, 2025, with 32.00% growth. This brings the company's revenue in the last twelve months to 1.08M, up 8.00% year-over-year. In the year 2024, Senhwa Biosciences had annual revenue of 1.00M.
Revenue (ttm)
1.08M
Revenue Growth
+8.00%
P/S Ratio
4,013.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | 1.00M | 450.00K | 81.82% |
| Dec 31, 2021 | 550.00K | -67.00K | -10.86% |
| Dec 31, 2020 | 617.00K | 317.00K | 105.67% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.59B |
| BioGend Therapeutics | 222.34M |
| Energenesis Biomedical CO.,LTD. | 7.46M |
| Formosa Pharmaceuticals | 12.16M |
| ACRO Biomedical | 36.50M |
| OBI Pharma | 49.29M |
| Locus Cell | 5.18M |
| Genovate Biotechnology | 492.41M |
Senhwa Biosciences News
- 6 months ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga